Medindia

X

Valeant Pharmaceuticals to Webcast 2011 Annual Meeting of Shareholders

Wednesday, May 11, 2011 General News J E 4
Advertisement

MISSISSAUGA, Ontario, May 11, 2011 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX) (TSX: VRX) today announced that it will conduct a live webcast of the company's annual meeting of shareholders.  The meeting and webcast will be held on Monday, May 16, 2011, at 10:00 a.m. EDT at the Loews Hotel Vogue located at 1425 rue de La Montagne, Montreal, Quebec H3G 1Z3.  Only shareholders of record at the close of business on the record date will be entitled to vote at the meeting and any adjournments or postponements thereof.

A live webcast and audio archive of the presentation will be available on the company's Web site at www.valeant.com. Click on Investor Relations, and then the link to Events and Presentations.  Participants should allow approximately five to ten minutes prior to the presentation's start time to visit the site and download any streaming media software needed to listen to the Internet webcast.

About Valeant

Valeant Pharmaceuticals International, Inc. (NYSE/TSX: VRX) is a multinational specialty pharmaceutical company that develops, manufactures and markets a broad range of pharmaceutical products primarily in the areas of neurology, dermatology and branded generics.  More information about Valeant can be found at www.valeant.com.

Contact Information:Laurie W. Little 949-461-6002 laurie.little@valeant.com

(Logo: http://photos.prnewswire.com/prnh/20101025/LA87217LOGO)

SOURCE Valeant Pharmaceuticals International, Inc.

Advertisement


Advertisement

You May Also Like

Advertisement
View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
s
Leading U.S. Healthcare Systems Implement TIGR Int...
S
Micell Technologies Reports Preclinical Data for M...